- Home
- EAF vs NMRA Comparison
EAF vs NMRA Comparison
Compare EAF & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- NMRA
- Stock Information
- Founded
- EAF 1886
- NMRA 2019
- Country
- EAF United States
- NMRA United States
- Employees
- EAF N/A
- NMRA N/A
- Industry
- EAF Industrial Machinery/Components
- NMRA
- Sector
- EAF Energy
- NMRA
- Exchange
- EAF Nasdaq
- NMRA Nasdaq
- Market Cap
- EAF 238.5M
- NMRA 268.5M
- IPO Year
- EAF 1995
- NMRA 2023
- Fundamental
- Price
- EAF $9.92
- NMRA $1.68
- Analyst Decision
- EAF Hold
- NMRA Buy
- Analyst Count
- EAF 6
- NMRA 8
- Target Price
- EAF $17.00
- NMRA $7.14
- AVG Volume (30 Days)
- EAF 217.2K
- NMRA 445.6K
- Earning Date
- EAF 07-25-2025
- NMRA 08-06-2025
- Dividend Yield
- EAF N/A
- NMRA N/A
- EPS Growth
- EAF N/A
- NMRA N/A
- EPS
- EAF N/A
- NMRA N/A
- Revenue
- EAF $508,550,000.00
- NMRA N/A
- Revenue This Year
- EAF N/A
- NMRA N/A
- Revenue Next Year
- EAF $19.47
- NMRA N/A
- P/E Ratio
- EAF N/A
- NMRA N/A
- Revenue Growth
- EAF N/A
- NMRA N/A
- 52 Week Low
- EAF $5.50
- NMRA $0.61
- 52 Week High
- EAF $25.30
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- EAF 43.00
- NMRA 52.17
- Support Level
- EAF $8.97
- NMRA $1.69
- Resistance Level
- EAF $10.75
- NMRA $1.84
- Average True Range (ATR)
- EAF 0.84
- NMRA 0.10
- MACD
- EAF -0.11
- NMRA -0.01
- Stochastic Oscillator
- EAF 23.00
- NMRA 43.64
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.